Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Hypercholesterolemia, Coronary Disease, Primary Health Care, Management, Risk
Interventions: HeartAge intervention; Behavioral
Lead sponsor: Memorial Hospital of Rhode Island; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5,218 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Pawtucket, Rhode Island

Conditions: Inflammation, Atherosclerosis, Hypercholesterolemia
Interventions: Simvastatin 40mg, Ezetimibe 10mg; Drug
Lead sponsor: paresh Dandona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hypertriglyceridemia
Interventions: Diazoxide choline, Placebo; Drug
Lead sponsor: Essentialis, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: Los Angeles, California • Jacksonville, Florida • Miami Gardens, Florida + 8 more

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: ALN-PCSSC, Standard of Care; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 12 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension, Hyperlipidemias
Interventions: Penn Med Healthy Heart Program; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 35 Years to 80 Years
Enrollment: 1,980 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Coronary Heart Disease, Stroke, Hyperlipidemia, Hypertension
Interventions: Enhance health lifestyle changes and medication compliance; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 35 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions: bempedoic acid; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio

Conditions: Hypercholesterolemia, Familial Hypercholesterolemia
Interventions: Enlicitide Decanoate, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 49
States / cities: Daphne, Alabama • Foley, Alabama • Phoenix, Arizona + 45 more

Conditions: Heart Disease, Ischemic, Hyperlipidemias, Hypertension
Interventions: Whole-Food, Plant-Based Diet and Low-Carbohydrate Diet; Other
Lead sponsor: University of Rochester; Other
Eligibility: 50 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Webster, New York

Conditions: Insulin Resistance, Cardiovascular Diseases, Heart Diseases, HIV Infections, Hypertriglyceridemia, Hyperlipidemia
Interventions: Acipimox; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hyperlipidemia
Interventions: Evacetrapib, Atorvastatin, Ezetimibe, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 61
States / cities: Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 56 more

Conditions: Heterozygous or Homozygous Familial Hypercholesterolemia
Interventions: Inclisiran; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 100 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 5
States / cities: Boca Raton, Florida • New York, New York • Cincinnati, Ohio + 2 more

Conditions: Elevated Triglycerides, Diabetes, Cardiovascular Disease
Interventions: Fructose, Fructose and Glucose; Dietary Supplement
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Evaluation of Plasma Lipoproteins
Interventions: Balanced diet; Behavioral
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 99 Years
Enrollment: 1,017 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1979
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections, Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions: Tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 19
States / cities: Los Angeles, California • San Diego, California • Denver, Colorado + 11 more

Conditions: Familial Hypercholesterolemia
Interventions: Implitapide; Drug
Lead sponsor: Medical Research Laboratories International; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Type 2 Diabetes, Hyperlipidemia, Hypertension, Depression
Interventions: Standard CQI intervention, Chronic Care Improvement (CCI) Intervention, Self-directed practice comparison; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 1,565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Standard of care; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 78
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more

Conditions: Cardiovascular Disease, Hypertension, Diabetes, Hyperlipidemia
Interventions: Pharmacist CVD; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hyperlipidemia
Interventions: AEGR-733, placebo, AEGR-733 and atorvastatin, AEGR-733 and fenofibrate, AEGR-733 and ezetimibe; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: San Diego, California • Santa Rosa, California • Washington D.C., District of Columbia + 10 more

Conditions: HIV Infections
Interventions: Pravastatin, Gemfibrozil, Rosiglitazone; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyperlipidemia, Diabetes, Hypertension
Interventions: Telepharmacist intervention; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 4,078 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Newton, Massachusetts

Conditions: Hyperlipidemia, NAFLD
Interventions: VK2809, Placebo; Drug
Lead sponsor: Viking Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 19
States / cities: Chandler, Arizona • Garden Grove, California • Los Angeles, California + 13 more

Conditions: Hypercholesterolemia
Interventions: Cottonseed Oil, Olive Oil; Dietary Supplement
Lead sponsor: University of Georgia; Other
Eligibility: 30 Years to 75 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Athens, Georgia

Search by objective public record fields.

Translating ATP III Cholesterol Management Guidelines Into Primary Care Practice

Anti-inflammatory Effects of Simvastatin

Diazoxide Choline in Hypertriglyceridemia

A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Penn Medicine Healthy Heart

Heart Disease on the Mend

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

Low-Carbohydrate and Plant-Based Dietary Effects on Vascular Health

Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

Fructose-Induced Palmitate Synthesis in Overweight Subjects

Evaluation of Lipoproteins

Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy

Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy

Using Learning Teams for Reflective Adaptation for Diabetes and Depression

Open Label Study of Long Term Evaluation Against LDL-C Trial

Cardiovascular Intervention Improvement Telemedicine Study

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

Endothelial Dysfunction as a Risk Factor in HIV Study

Tele-Pharmacy Intervention to Improve Treatment Adherence

Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

Oil Consumption and Cholesterol